Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 9, 2002International Journal of CancerOpen Access

In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine)

View Full Paper
Ask AI
Bookmark
Share

Authors

SMSteven J. McClueDBDavid BlakeRCRosemary G. Clarke

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

McClue et al. (2002) studied this question.

synapsesocial.com/papers/6a173fdabdf43c780a785bb4https://doi.org/10.1002/ijc.10738
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Prognostic Significance of Altered Cyclin-Dependent Kinase Inhibitors in Human Cancer1999 · 321 citations
  2. 2Inhibition of Cyclin‐Dependent Kinases by Purine Analogues1994 · 629 citations
  3. 3Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin‐Dependent Kinases cdc2, cdk2 and cdk51997 · 1,361 citations
  4. 4p53 Website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis2000 · 271 citations